Abstracts

Early Identification of ART Missed Doses: Baseline Data From the RETAIN Study

Background: We present baseline data from ‘Improving RETention and viral load outcomes for people taking Antiretroviral therapy through early IdentificatioN of missed doses (RETAIN)’, a cohort study exploring detailed adherence metrics [viral load (VL), electronic adherence monitoring (EAM); tenofovir diphosphate (TFV-DP) concentrations and self-report (SR)] in people on ART, when initially flagged for reduced adherence.…

Adherence Markers for Doxy-PEP in Plasma and Urine

Background: Clinical trials of Doxy-PEP demonstrated high efficacy in preventing bacterial sexually transmitted infections (STIs) among men who have sex with men but not in women. Low Doxy-PEP efficacy observed among women may be related to poor adherence highlighting the importance of objective adherence monitoring in future trials and implementation studies. We examined doxycycline (DOXY)…

Safety and PK/PD of a Tenofovir Rectal Douche Administered in Different Sequences, DREAM-03

Background: On-demand and behaviorally congruent forms of HIV pre-exposure prophylaxis (PrEP) have long been requested by communities at risk of HIV, especially men who have sex with men (MSM). Previously in DREAM-01, we reported safety, acceptability, and pharmacokinetics/pharmacodynamics (PK/PD) of three single-dose tenofovir (TFV) rectal douche formulations in MSM and identified a lead formulation. Given…

Tenofovir Diphosphate Benchmarks in Dried Blood Spots in PWH Receiving TAF-Based ART (QUANTI-TAF)

Background: Tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBS) in people with HIV (PWH) receiving tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) are not defined. QUANTI-TAF (NCT04065347) aimed to establish adherence:concentration benchmarks in PWH receiving TAF-based ART by quantifying TFV-DP concentrations in DBS, leveraging digital pills to organically capture directly observed therapy (DOT) adherence in…

Evidence for Safe Use of Doravirine With Hormonal Contraceptives in African Women Living With HIV

Background: Prior to scale-up of new ART, exploring drug-drug interactions between ART and contraceptive methods is crucial. We are conducting EPIC, a parallel group pharmacokinetic study to examine interactions with doravirine (DOR)-containing ART among women of reproductive potential living with HIV in Johannesburg, South Africa. Methods: EPIC began in November 2021 and is ongoing. A…

Hepcidin Modifies Effects of Age and Erythrocyte Indices on Cognitive Function in People With HIV

Background: Cognitive impairment (CI) in people with HIV (PWH) is associated with abnormal erythrocyte indices, which may result from inflammation, disturbed iron metabolism, and other factors. Mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) are indices of erythrocyte volume and hemoglobinization, which help to classify anemia. Erythropoiesis requires bioavailable iron, levels of which are…

Clinical Profiles Predicting Cognitive Decline Over 10 Years Among Older Adults With HIV in Canada

Background: Correlates of cognitive impairment in older adults with HIV (OAWH) have been identified cross-sectionally, but much less is known about the clinical profiles predicting cognitive decline over several years among ART-treated OAWH. Methods: The Positive Brain Health Now cohort included 856 individuals (mean age 53 years) from 5 HIV clinics in Canada between 2013-2016.…

High Plasma GFAP in Older PWH With Low Nadir CD4 Supports Legacy Brain Injury and Reactive Gliosis

Background: Measuring cerebrospinal or plasma levels of brain injury markers may provide useful information on HIV neuropathogenesis and help characterize cognitive impairment in PWH. We compared plasma levels of these markers to cognitive function, physical performance and history of HIV in PWH≥50 years Methods: 102 ART-treated PWH ≥50 years and 40 age-matched controls without HIV…